Novo Nordisk (NVO) settlement on the out-of-pocket price cap of insulin for Minnesota residents at $35 per month for the next five years was approved by a federal court in New Jersey, Bloomberg reported Wednesday, citing a court document.
US District Judge Brian Martinotti approved the settlement on Tuesday, according to news outlet. The settlement will cover residents regardless of their insurance status and make the medicine to treat diabetes free for the poorest residents.
Minnesota sued Novo Nordisk in 2018, alleging it engaged in a racketeering enterprise with pharmacy benefit managers to inflate the price of its insulin products, per the news outlet.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Price: 72.02, Change: -1.58, Percent Change: -2.15
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.